Seventeen antipsychotic medications are available in the U.S. Antipsychotic formulary considerations include relative efficacy, individual patient response, relative differences in adverse effects, dosage form availability, blood level monitoring, and generic availability. Chlorpromazine, thioridazine, haloperidol, and fluphenazine are recommended for formulary inclusion based on research and clinical considerations. A recommendation for managing a patient receiving a nonformulary antipsychotic is presented.
ResnickM, BurtonBT. Droperidol vs. haloperidol in the initial management of acutely agitated patients.J Clin Psychiatry1984; 45: 2989.
3.
ColvinCL, TankanowRM. Pimozide: use in Tourette's syndrome.Drug Intell Clin Pharm1985; 19: 4214.
4.
FreinharJP. Delusions of parasitosis.Psychosomatics1984; 25: 4753.
5.
OrtizA, GershonS. The future of neuroleptic psychopharmacology.J Clin Psychiatry1986; 47(suppl): 311.
6.
RaskindMA, RisseSC. Antipsychotic drugs and the elderly.J Clin Psychiatry1986; 47(suppl): 1722.
7.
KaneJM, HonigfeldG. Multicenter trial of clozapine: designs, methods, and clinical results. Presented at the NCDEU annual meeting. May 25-28, 1987, Key Biscayne, FL.
BlackJL, RichelsonE. Antipsychotic drugs: prediction of side-effect profiles based on neuroreceptor data derived from human brain tissue.Mayo Clin Proc1987; 62: 36972.
Van PraagHM, DolsLCW. Fluphenazine enanthate and decanoate: a comparison of their duration of action and motor side effects.Am J Psychiatry1973; 130: 8014.
